RxDoctor Payments Data

Noam Harpaz, MD

Anatomic Pathology & Clinical Pathology · New York, NYNPI 1710987623

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,100 of the $3,100 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Eli Lilly. Among anatomic pathology & clinical pathology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,100in general payments, 2019–2025

Across 2 payments — averaging $1550.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3K
$502,439in research payments, 2019–2025

Across 5 payments — averaging $100,488 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$296K
  • Janssen Research & Development, LLC$207K

What the payments were for

  • Consulting fees$3,100100%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly2$3,100

How this compares

$3,100 in reported general payments places this provider in the 90th percentile of 468 anatomic pathology & clinical pathology providers in New York.

See all anatomic pathology & clinical pathology providers in New York

Medicare billing

Part B allowed, 2024
$117,890
Medicare patients
503
Services billed
1,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →